Online citations, reference lists, and bibliographies.
← Back to Search

Preclinical Pharmacologic Evaluation Of MST-997, An Orally Active Taxane With Superior In Vitro And In Vivo Efficacy In Paclitaxel- And Docetaxel-Resistant Tumor Models

D. Sampath, L. Greenberger, C. Beyer, Malathi Hari, H. Liu, Michelle Baxter, Sharon Yang, Carol Rios, C. Discafani
Published 2006 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Purpose: Because resistance to paclitaxel and docetaxel is frequently observed in the clinic, new anti-microtubule agents have been sought. The aim of this study was to evaluate the efficacy and oral activity of a novel taxane (MST-997) in paclitaxel- and docetaxel-resistant tumor models in vitro and in vivo. Experimental Design: Tubulin polymerization assays, immunohistochemistry, and cell cycle analysis was used to evaluate mechanism of action of MST-997. The effect of MST-997 on growth inhibition in a panel of paclitaxel- and docetaxel-resistant cell lines that overexpressed P-glycoprotein (MDR1) or harbored β-tubulin mutations were assayed in vitro and in murine xenografts. Results: MST-997 induced microtubule polymerization (EC50 = 0.9 μmol/L) and bundling, resulting in G2-M arrest and apoptosis. In addition, MST-997 was a potent inhibitor of paclitaxel- and docetaxel-sensitive tumor cell lines that did not have detectable P-glycoprotein (IC50 = 1.8 ± 1.5 nmol/L). Minimal resistance (1- to 8-fold) to MST-997 was found in cell lines that either overexpressed MDR1 or harbored point mutations in β-tubulin. Most notable, MST-997 displayed superior in vivo efficacy as a single i.v. or p.o. dose either partially or completely inhibited tumor growth in paclitaxel- and docetaxel-resistant xenografts. Conclusions: MST-997 represents a potent and orally active microtubule-stabilizing agent that has greater pharmacologic efficacy in vitro and in vivo than the currently approved taxanes. Our findings suggest that MST-997, which has entered phase I clinical trials, may have broad therapeutic value.
This paper references
10.1038/222665A0
Exchange Coupling in Two Dimeric Copper Adenine Complexes
R. W. Duerst (1969)
10.1021/JA00738A045
Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.
M. Wani (1971)
Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemia and antitumor agent from
M. Wani (1971)
Plant antitumor agentsVI.The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevefolia
M C Wani (1971)
Plant antitumoragentsVI . The isolationand structure of taxol , a novel antileukemic and antitumor agent from Taxusbrevefolia
MC Wani (1971)
10.1038/277665a0
Promotion of microtubule assembly in vitro by taxol
P. Schiff (1979)
Promotion of microtubules assembly in vitro byTaxol
PB Schiff (1979)
10.1083/JCB.91.2.479
Taxol binds to polymerized tubulin in vitro
J. Parness (1981)
10.1016/s0021-9258(19)57466-x
Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins.
D. Shen (1986)
10.1007/978-1-4615-3794-6_4
Isolation and Characterization of the Human MDR (P-Glycoprotein) Genes
I. Roninson (1991)
10.1007/978-1-4615-3794-6
Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells
I. Roninson (1991)
Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.
M. Bissery (1991)
10.1016/0092-8674(91)90141-K
Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells
P. M. Chaudhary (1991)
10.1093/JNCI/83.4.288
Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol.
I. Ringel (1991)
10.1021/JM00107A017
Relationships between the structure of taxol analogues and their antimitotic activity.
F. Guéritte-Voegelein (1991)
Expression and activity of P - glycoprotein , a multidrug efflux pump , in human hematopoietic stem
PM Chaudhary (1991)
10.1016/0165-6147(92)90048-B
Mechanism of action of taxol.
S. Horwitz (1992)
10.1097/00001813-199208000-00001
Taxol: a review of its preclinical in vivo antitumor activity.
W. C. Rose (1992)
Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics Mechanism of action of taxol
Kh Downing (1992)
10.1002/9781118696194.ch2.3
[Antimicrotubule agents].
H. Niitani (1993)
10.1177/10600280940280S503
Pharmacology and Toxicology of Cremophor EL Diluent
R. Dorr (1994)
Pharmacology and toxicology of Cremo - phor EL diluent
RT Dorr (1994)
10.1002/CHIN.199552275
Semisynthesis of Taxol and Taxotere
R. Holton (1995)
Taxol®: science and applications.
M. Suffness (1995)
Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.
D. M. Bollag (1995)
alpha-(3,4-dimethyoxyphenyl)-3,4-dihydro-6,7-dimethoxy-alpha- [(4-methylphenyl)thio]-2(1H)-isoquinolineheptanenitrile (CL 329,753): a novel chemosensitizing agent for P-glycoprotein-mediated resistance with improved biological properties compared with verapamil and cyclosporine A.
L. Greenberger (1996)
MDR1expression in sold tumors
L J Goldstein (1996)
MDR 1 expression in sold tumors
LJ Goldstein (1996)
10.1074/jbc.272.27.17118
Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization*
P. Giannakakou (1997)
10.2165/00044011-199714050-00011
Hypersensitivity Reactions to the Taxanes Paclitaxel and Docetaxel
V. Panday (1997)
10.1038/bjc.1997.530
Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
J. van Asperen (1997)
Paclitaxel pharmacology and other tumor types.
E. Rowinsky (1997)
10.1073/PNAS.94.5.2031
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.
A. Sparreboom (1997)
10.1073/PNAS.95.7.3896
Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis.
P. Moos (1998)
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
J. M. Meerum Terwogt (1999)
10.1006/JMBI.1998.2303
Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein.
Diane J. Rodi (1999)
10.1016/S1074-5521(99)80004-0
High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications.
B. Stockwell (1999)
10.1200/JCO.1999.17.3.1061
Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death.
C. Dumontet (1999)
10.1200/JCO.1999.17.6.1786
Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.
M. Monzó (1999)
Highthroughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications
B R Stockwell (1999)
Cell-based screen for antimitotic agents and identification of analogues of rhizoxin, eleutherobin, and paclitaxel in natural extracts.
M. Roberge (2000)
10.1016/S0304-419X(00)00009-3
Epothilones and related structures--a new class of microtubule inhibitors with potent in vivo antitumor activity.
K. Altmann (2000)
10.1146/ANNUREV.CELLBIO.16.1.89
Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics.
K. Downing (2000)
10.1007/s002800000241
Preclinical antitumor activity of two novel taxanes
W. C. Rose (2000)
10.1007/s002800000137
Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivative
W. C. Rose (2000)
10.1073/PNAS.040546297
A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.
Paraskevi Giannakakou (2000)
Structural basis for the interaction of tubulinwith proteins and drugs that affectmicrotubule dynamics
KH Downing (2000)
10.1093/JNCI/93.24.1886
Genetic Analysis of the β-Tubulin Gene, TUBB, in Non-Small-Cell Lung Cancer
M. Kelley (2001)
10.2165/00003088-200140030-00002
The Gut as a Barrier to Drug Absorption
Y Zhang (2001)
MUTATIONS IN BETATUBULIN MAP TO DOMAINS INVOLVED IN REGULATION OF MICROTUBULE STABILITY IN EPOTHILONE-RESISTANT CELL LINES
L. he (2001)
10.1016/S1470-2045(01)00486-7
Global cancer statistics in the year 2000.
D. Parkin (2001)
Genetic analysis of the h - tubulin gene , TUBB , in non - small - cell lung cancer
KelleyMJ (2001)
Genetic analysis of the h-tubulin gene, TUBB, in non-small-cell lung cancer
M J Kelley (2001)
Mutations in h-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines
L He (2001)
10.1016/S0169-5002(01)00291-4
Mutational analysis of the β-tubulin gene in lung cancer
J. Tsurutani (2002)
10.1038/nrc706
Multidrug resistance in cancer: role of ATP–dependent transporters
M. Gottesman (2002)
Conservation of the Class I -Tubulin Gene in Human Populations and Lack of Mutations in Lung Cancers and Paclitaxel-resistant Ovarian Cancers 1
S. Šale (2002)
10.1093/ANNONC/MDF093
Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic.
R. Kerbel (2002)
10.1002/ijc.10601
Lack of β‐tubulin gene mutations in early stage lung cancer
M. Kohonen-Corish (2002)
10.1002/ijc.10575
Mutational analysis of the class I β‐tubulin gene in human breast cancer
S. Hasegawa (2002)
Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers.
S. Šale (2002)
Lack of h-tubulin gene mutations in early stage lung cancer
M R Kohonen-Corish (2002)
Lack of h - tubulin gene mutations in early stage lung cancer
Kohonen-CorishMR (2002)
Mutational analysis of the h - tubulin gene in
J Tsurutani (2002)
Lack of h - tubulin gene mutations in early stage lung cancer
Kohonen-CorishMR (2002)
MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.
D. Sampath (2003)
HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
F. Loganzo (2003)
10.1023/A:1010635000879
Oral Delivery of Taxanes
M. Malingré (2004)
10.1158/1535-7163.MCT-05-0190
Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules
Malathi Hari (2006)
10.1007/978-1-59745-035-5_18
Resistance To Taxanes
L. Greenberger (2006)
10.1007/978-1-59745-035-5
Cancer Drug Resistance
B. Teicher (2006)
Cancer Therapy: Preclinical www.aacrjournals.org Clin Cancer Res
(2006)
American Association for Cancer clincancerres.aacrjournals.org Downloaded from
(2006)
Resistance to taxanes In: Teicher BA, editor. Cancer drug resistance
L Greenberger (2006)
MST-997, a Novel Orally Active and Improved Taxane www
(2006)
10.1007/BF02614214
Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere®)
D. Dykes (2007)
Clin Cancer Res



This paper is referenced by
10.1016/B978-0-12-823975-9.00004-3
Drug metabolism and pharmacokinetic diversity of Taxus medicinal compounds
D. Hao (2021)
10.1016/j.drup.2020.100742
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.
L. Mosca (2021)
10.1016/j.ejmech.2018.07.011
Discovery of the cancer cell selective dual acting anti-cancer agent (Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitrile (A131).
Cheng Shang See (2018)
10.1159/000477116
Cytosolic Cl- Affects the Anticancer Activity of Paclitaxel in the Gastric Cancer Cell Line, MKN28 Cell
Sachie I. Tanaka (2017)
10.1016/j.pharmthera.2015.12.006
Microtubule-stabilizing agents: New drug discovery and cancer therapy.
Ying-Ze Zhao (2016)
10.1007/978-81-322-1184-6_30
Pharmacogenomics of Gynecological Disorders
Jaspreet Kaur (2013)
10.1016/J.CHEMOLAB.2011.03.012
Development of Classification Model batteries for predicting inhibition of tubulin polymerization by small molecules
I. Massarelli (2011)
10.1038/sj.bjc.6606007
Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma
Linhua Jin (2011)
Pharmacokinetic Optimization of 4-Substituted Methoxybenzoyl-Aryl-Thiazole (SMART) and 2-Aryl-4-Benzoyl-Imidazole (ABI) for Improving Oral Bioavailability
R. Narayanan (2011)
10.1124/dmd.110.036616
Pharmacokinetic Optimization of 4-Substituted Methoxybenzoyl-aryl-thiazole and 2-Aryl-4-benzoyl-imidazole for Improving Oral Bioavailability
Chien-Ming Li (2011)
10.1016/j.nucmedbio.2009.08.007
Influence of chemoresistance and p53 status on fluoro-2-deoxy-D-glucose incorporation in cancer.
T. Smith (2010)
10.25772/XS7A-B628
CELL DEATH AND SUSTAINED SENESCENCE ARREST IN COLON CARCINOMA AND MELANOMA TUMOR CELLS IN RESPONSE TO THE NOVEL MICROTUBULE POISON, JG-03-14
Jonathan W. Biggers (2010)
10.1517/13543770902775713
Microtubule stabilising agents for cancer chemotherapy
Ying-Ze Zhao (2009)
10.1158/0008-5472.CAN-08-1420
Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B.
E. Hopper-Borge (2009)
10.1158/1078-0432.CCR-08-0550
N-(2,6-Dimethoxypyridine-3-yl)-9-Methylcarbazole-3-Sulfonamide as a Novel Tubulin Ligand against Human Cancer
Yue-ming Wang (2008)
10.1016/J.BBCAN.2007.10.004
Taxanes, microtubules and chemoresistant breast cancer.
Barbara McGrogan (2008)
10.1002/cmdc.200600308
Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes
E. Galletti (2007)
10.1016/J.AB.2006.10.014
Promotion of tubulin assembly by poorly soluble taxol analogs.
Shubhada Sharma (2007)
10.1186/1471-2105-9-76
Response projected clustering for direct association with physiological and clinical response data
S. Yi (2007)
Semantic Scholar Logo Some data provided by SemanticScholar